All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
3 warning events since 2017; the latest 2025-08-12.
From the record
Marker Therapeutics, Inc.'s filings since 2017 show 3 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 2 times, the latest 2022-08-19); an auditor change (8-K item 4.01, the latest 2025-08-12) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+59.8% a year over 7 filed years; profitable in 0 of 7.
From the record
Marker Therapeutics, Inc.'s 7 filed years say what it did: revenue went from $213 thousand in fiscal 2019 to $4 million in fiscal 2025, up 59.8% a year; it rose in 4 of 6 years; the deepest fall was 46% from fiscal 2024 to fiscal 2025; net income was positive in 0 of 7 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 4.7/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Marker Therapeutics, Inc.'s shareholder treatment is put at 4.7 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 47% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -72%: lost 72¢ per shareholder dollar. Leverage 12%: owes 12¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Marker Therapeutics, Inc. lost about 72 cents for every dollar of shareholders' money. Leverage: it owed about 12 cents per dollar of assets, and net share issuance: its share count grew 70.5% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 37% of 315 in its family; net margin -343%.
From the record
Marker Therapeutics, Inc.'s standing among 315 graded names in its industry family: revenue of $4 million in fiscal 2025 ranks in the bottom 32% by size; a net margin of -343% ranks in the bottom 41%; revenue growth of 0.3% a year over the last 3 filed years ranks in the bottom 39% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 41% of 315 in its family for leadership; chief executive since 2023.
From the record
Marker Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Vera, Juan (Chief Executive Officer, as filed), filing under that title since 2023-05-11, 3.5 years (bottom 37% of its family); the 5 officers and directors filing in the last fifteen months have been on the record a median of 7.3 years (top 26%); 5 officer or director changes were reported on Form 8-K since 2023-11-13, against the 5 people in charge now (bottom 11%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 37% of 273 in its family for room to expand.
From the record
Marker Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $16 million against no long-term debt tagged leaves 84.3% of its assets as net cash, top 15% of its family; cash from operations less capital spending is -338.7% of revenue (bottom 40%); research spending of 332.7% of revenue (top 36%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 24% of 306 in its family for growth drivers.
From the record
Marker Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 0.3% a year over the last three filed years against 59.8% over all 7, slowing (bottom 9% of its family); the newest year grew -46.2% (bottom 17%); research spending grew -0.5% a year (bottom 47%) (its annual reports). Marker Therapeutics, Inc. reported 7 product lines in fiscal 2025: Cancer Prevention and Research Institute of Texas Acute Myeloid Leukemia at $900 thousand (25%), National Institutes of Health Small Business Innovation Research for Lymphoma Grant at $665 thousand (19%), Cprit Pancreatic Grant at $574 thousand (16%), and 4 more; 2 of 6 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 46% of 233 in its family for expectations against reality.
From the record
Marker Therapeutics, Inc.'s newest year against its own record: revenue of $4 million in fiscal 2025 came in 60.7% below the $9 million its prior three years' pace pointed to (bottom 16% of its family); net income of $12 million against a prior three-year average of $16 million (top 44%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 34%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made